Neoadjuvant Osimertinib Followed by Sequential Definitive Radiotherapy and/or Surgery in Patients With Stage III EGFR-Mutant NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
International Journal of Radiation Oncology, Biology, Physics
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Neoadjuvant osimertinib followed by sequential definitive radiotherapy and/or surgery in stage III EGFR-mutant NSCLC: An open-label, single-arm, phase II study
Int. J. Radiat. Oncol. Biol. Phys 2023 Mar 14;[EPub Ahead of Print], N Peled, LC Roisman, E Levison, J Dudnik, E Chernomordikov, N Heching, E Dudnik, S Keren-Rosenberg, H Nechushtan, A Salhab, D Hershkovitz, S Tsuriel, V Hannes, O Rotem, I Lazarev, R Lichtenberg, IS Granot, B Krayim, W Shalata, D Levin, Y Krutman, AM Alon, P Blumenfeld, K Lavrenkov, W KianFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.